Table 3.

Clinical Trials for Non-Treatment Candidates.

Study	Citation	Study Design	Intervention	Number of participants (n)	Rates of major/severe hemorrhage (Treatment versus Control)	Outcome
THALES	Johnston et al. NEJM 2020 [36]	Randomized, double-blind, placebo- controlled trial	Randomization within 24 hours of symptom onset	11,016	0.5% vs 0.1%, (P=0.001)	Lower risk of stroke or death within 30 days but increase risk of major hemorrhage.
POINT	Johnston et al. NEJM 2018 [25]	Randomized, double-blind multicenter trial	Randomization within 12 hours of symptom onset	4881	0.9% vs 0.4%, (P=0.02)	Lower risk of major ischemic events but a higher risk of major hemorrhage at 90 days
CHANCE	Wang et al. NEJM 2013 [24]	Randomized, double-blind, placebo- controlled trial	Randomization within 24 hours of symptom onset	5170	0.3% vs 0.3%, (P=0.73)	Lower risk of stroke but no increase risk of major hemorrhage at 90 days